Sermorelin (GHRH(1–29)-NH₂) is the biologically active N-terminal 29-amino acid fragment of native human growth hormone-releasing hormone, produced as the acetate salt for research applications. As the minimal sequence retaining full GHRH-R binding affinity and biological activity, sermorelin represents the reference compound in GH secretagogue research against which longer analogues (CJC-1295, tesamorelin) and non-GHRH-class compounds (ipamorelin) are benchmarked. Its pharmacological simplicity — no albumin conjugation, no lipid modification — makes it the preferred tool for studying native GHRH-R signaling kinetics without confounders introduced by extended-release chemistry.
GHRH-R Activation and cAMP/PKA/CREB Signaling Cascade
Sermorelin activates the type 1 GHRH receptor (GHRH-R1) with EC₅₀ values of 0.3–0.7 nM in anterior pituitary membrane preparations, indistinguishable from native GHRH(1–44). Receptor occupancy by sermorelin initiates Gsα-mediated adenylyl cyclase activation, generating intracellular cAMP concentrations that peak within 2–3 minutes of peptide exposure (3.2 ± 0.6 pmol/mg protein at 10 nM, versus 0.8 pmol/mg in vehicle controls, p<0.001). PKA activation (as measured by PKA regulatory subunit dissociation) peaks at 5–7 minutes and phosphorylates CREB at Ser133.
Phospho-CREB drives transcription of the GH gene (Gh1) and upregulates GHRH-R expression via a positive feedback loop, increasing somatotroph sensitivity to subsequent stimulation. Concurrently, Ca²⁺ influx through voltage-gated L-type channels amplifies GH exocytosis: sermorelin at 1 nM in isolated somatotroph preparations elicits Ca²⁺ transients of 180 ± 22 nM peak (versus 42 ± 8 nM basal, p<0.001) within 60–90 seconds of application.
Somatotroph Activation and GH Secretion Kinetics
Sermorelin acts exclusively on GHRH-R-expressing pituitary somatotrophs and hypothalamic somatotroph progenitors. It does not bind GHS-R1a, does not stimulate ACTH or cortisol secretion, and produces no measurable prolactin response at research concentrations up to 10 µg/kg in rodent models. This clean receptor profile made sermorelin the FDA-approved diagnostic agent for GH deficiency testing (1998–2008, Geref diagnostic) and the basis for comparison in neuroendocrine challenge protocols.
In human pharmacodynamic studies, intravenous sermorelin at 1 µg/kg produced peak GH of 18.4 ± 5.2 ng/mL in healthy adults (mean age 28 ± 4 years), with GH AUC(0–90 min) of 1244 ± 310 ng·min/mL. GH-deficient adults showed peak GH of 3.2 ± 1.8 ng/mL (p<0.001 versus healthy controls), establishing the clinical diagnostic threshold. Subcutaneous administration produces lower peak GH with area equivalent absorption: Tmax shifts from 15–20 minutes (IV) to 30–45 minutes (SC), with bioavailability ~70–85%.
Pharmacokinetics: Half-Life, Degradation, and Tissue Distribution
Sermorelin has a plasma half-life of 10–12 minutes following intravenous administration in humans, determined by rapid proteolytic cleavage at the N-terminal Tyr1-Ala2 bond by dipeptidyl aminopeptidase and at internal sites by neutral endopeptidase 24.11 (neprilysin). The C-terminal amidation of Gly29 (-NH₂) confers modest resistance to carboxypeptidase degradation, extending activity relative to the non-amidated form by ~40% in plasma stability assays.
Subcutaneous depot formation extends effective exposure: despite the short plasma half-life, GH responses persist for 60–90 minutes post-injection due to continued peptide absorption from the injection site. Tissue distribution is limited; there is no documented blood-brain barrier penetration. Renal clearance accounts for approximately 65% of elimination, with hepatic biotransformation contributing the remainder.
IGF-1 Response and Downstream JAK2/STAT5b Pathway
Chronic sermorelin administration (daily or twice-daily SC protocols) sustains IGF-1 elevation through repeated GH pulse amplification. In a 6-month open-label study in adult GH-deficient subjects (n=47), nightly sermorelin at 0.03 mg/kg SC elevated IGF-1 from 112 ± 34 µg/L to 218 ± 58 µg/L (95% increase, p<0.001 by paired t-test). The IGF-1 SDS score improved from −2.3 ± 0.8 to −0.7 ± 0.6 (p<0.001).
Hepatic JAK2 autophosphorylation (Tyr1007/1008) in response to repeated GH pulses drives STAT5b dimerization and nuclear translocation, which upregulates IGF-1 gene transcription (Igf1 mRNA +180% versus baseline in chronic GH-pulsed hepatocyte cultures, p<0.001). Downstream, PI3K/Akt/mTOR activation increases in proportion to IGF-1 exposure duration, with mTORC1-mediated protein synthesis rates increasing 35–50% above baseline in skeletal muscle under chronic IGF-1 conditions simulating sermorelin-driven GH profiles.
Research Specifications and Quality Parameters
Alpha Nordisk sermorelin acetate contains the sequence H-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH₂ (GHRH(1–29)-NH₂), MW 3357.93 Da, confirmed by LC-MS. HPLC purity >99% by UV214. Supplied as lyophilized acetate salt, lot-traceable per the Alpha code system (e.g., A26Q2SRM0204). Certificate of analysis accessible at alphanordisk.com/verify.
For research and laboratory use only. Not for unsupervised human consumption. Clinical data referenced reflect published pharmacodynamic studies under IRB-controlled conditions. Preclinical in vitro data are derived from validated somatotroph culture and hepatocyte models and do not constitute therapeutic claims.